AKT1 and idiopathic pulmonary fibrosis: These results collectively suggest that AS-IV exerts protective effects against IPF progression primarily through modulation of the PI3K-AKT pathway by targeting PIK3CA, supporting its potential development as a novel antifibrotic therapeutic agent.